Comparative Analysis Of Postoperative Vault In Staar Icl And Biotech Icl: Long-Term Outcomes At 1, 2, And 3 Years In 50 Patients

The purpose of this study is to compare postoperative vault between the  Staar ICL and Biotech ICL implants over a period of 3 years.

We aim to evaluate the impact of different ICL designs on vault stability and long-term visual and anatomical outcomes.

single surgeon private practice setup

The study will span 3 years, from patient recruitment to final follow-up.

50 patients, with 40 staar icl and 10 biotech icl

Inclusion Criteria: Patients aged 18-36 with stable refractive errors (myopia, hyperopia, or astigmatism), and suitable for ICL implantation.

Exclusion Criteria: Patients with corneal pathology, prior eye surgery, or uncontrolled systemic diseases.

Comprehensive eye examination including manifest refraction, visual acuity, slit-lamp biomicroscopy, IOP measurement, digital WTW measurement and fundus examination, Optical

UCVA, BCVA, refractive error (spherical equivalent), and vault measurement using Anterior Segment OCT will be assessed at each follow-up.

Vault Comparison:

Both designs maintained an ideal vault range in the majority of patients ,Staar ICL showed a slightly higher postoperative vault (around 417 µm after 3 years) compared to biotech ICL  (390 µm at 3 years).

In this , both Staar ICL and Biotech ICL were successful in providing stable refractive outcomes with minimal complications over a 3-year period. Staar ICL had a slightly more stable vault, lower complication rates, and higher patient satisfaction scores. However, both designs were effective in treating high refractive errors with acceptable safety profiles, making both options viable for clinical practice.